ES2018387A6 - Procedimiento de obtencion de un medicamento para inhibir la infeccion de celulas por virus hiv. - Google Patents

Procedimiento de obtencion de un medicamento para inhibir la infeccion de celulas por virus hiv.

Info

Publication number
ES2018387A6
ES2018387A6 ES8902912A ES8902912A ES2018387A6 ES 2018387 A6 ES2018387 A6 ES 2018387A6 ES 8902912 A ES8902912 A ES 8902912A ES 8902912 A ES8902912 A ES 8902912A ES 2018387 A6 ES2018387 A6 ES 2018387A6
Authority
ES
Spain
Prior art keywords
monoclonal antibody
viruses
inhibiting cell
cell infection
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES8902912A
Other languages
English (en)
Inventor
Dr Frank Emmrich
Dr Gerhard Hunsmann
Dr Wolfgang Luke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Primatenzentrum GmbH
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Deutsches Primatenzentrum GmbH
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Primatenzentrum GmbH, Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Deutsches Primatenzentrum GmbH
Publication of ES2018387A6 publication Critical patent/ES2018387A6/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PROCEDIMIENTO DE OBTENCION DE UN MEDICAMENTO PARA INHIBIR LA INFECCION DE CELULAS POR VIRUS HIV. PROCEDIMIENTO PARA PREPARAR UN MEDICAMENTO DESTINADO A PREVENIR UNA INFECCION POR HIV Y SIV Y/O LA PROPAGACION DE LOS VIRUS EN EL CUERPO DESPUES DE HABERSE PRODUCIDO LA INFECCION, CARACTERIZADO PORQUE COMPRENDE LAS OPERACIONES DE A) CULTIVAR LINEAS DE CELULAS DE HIBRIDOMA ECACC 88050502, B) SEPARAR LOS ANTICUERPOS MONOCLONADOS 30F16H5 PRODUCIDOS DEL MEDIO DE CULTIVO, Y C) INCORPORAR LOS ANTICUERPOS SEPARADOS EN MATERIALES FISIOLOGICAMENTE ACEPTABLES, EVENTUALMENTE JUNTO CON OTROS MATERIALES DE VEHICULO Y ADITIVOS USUALES, PARA OBTENER UNA FORMA DE ADMINISTRACION DE DICHOS ANTICUERPOS FARMACEUTICAMENTE APROPIADA.
ES8902912A 1988-08-23 1989-08-23 Procedimiento de obtencion de un medicamento para inhibir la infeccion de celulas por virus hiv. Expired - Lifetime ES2018387A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3828582A DE3828582A1 (de) 1988-08-23 1988-08-23 Monoklonaler antikoerper zur inhibierung der infektion von zellen durch hiv-viren

Publications (1)

Publication Number Publication Date
ES2018387A6 true ES2018387A6 (es) 1991-04-01

Family

ID=6361424

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8902912A Expired - Lifetime ES2018387A6 (es) 1988-08-23 1989-08-23 Procedimiento de obtencion de un medicamento para inhibir la infeccion de celulas por virus hiv.

Country Status (7)

Country Link
EP (1) EP0430999A1 (es)
JP (1) JPH04501055A (es)
AU (1) AU629847B2 (es)
DE (1) DE3828582A1 (es)
DK (1) DK24891A (es)
ES (1) ES2018387A6 (es)
WO (1) WO1990002199A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3919294C2 (de) * 1989-06-13 1998-04-23 Frank Prof Dr Emmrich Verwendung eines monoklonalen Antikörpers zur Behandlung einer Autoimmunerkrankung
US5961976A (en) * 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
EP2471543A1 (en) 2010-12-02 2012-07-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules
SG11201702056YA (en) 2014-09-16 2017-04-27 United Biomedical Inc Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition
CA3033728A1 (en) 2016-08-13 2018-02-22 Ubi Ip Holdings Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683295A (en) * 1984-05-24 1987-07-28 Scripps Clinic And Research Foundation Method for the preparation of anti-receptor antibodies
FR2570278B1 (fr) * 1984-09-14 1987-02-13 Pasteur Institut Compositions et procede pour proteger les lymphocytes t contre l'agent etiologique des lymphadenopathies et du syndrome d'immunodepression acquise
JP3134874B2 (ja) * 1986-08-21 2001-02-13 ザ・トラステイーズ・オブ・コロンビア・ユニヴアーシテイ・イン・ザ・シテイ・オブ・ニユー・ヨーク Ｔ細胞表面タンパク質ｔ４をコードするｄｎａ並びにｔ４フラグメントのａｉｄｓ治療への使用
FI891226L (fi) * 1988-04-28 1989-10-29 Univ Leland Stanford Junior Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
EP0380018B1 (en) * 1989-01-23 1995-07-19 Abbott Laboratories Rat monoclonal antibodies directed against human antigens and processes for preparation thereof

Also Published As

Publication number Publication date
DK24891D0 (da) 1991-02-13
DK24891A (da) 1991-02-13
JPH04501055A (ja) 1992-02-27
WO1990002199A1 (de) 1990-03-08
AU4070289A (en) 1990-03-23
AU629847B2 (en) 1992-10-15
DE3828582A1 (de) 1990-03-01
EP0430999A1 (de) 1991-06-12

Similar Documents

Publication Publication Date Title
ES8606289A1 (es) Un procedimiento para la preparacion de piridazinaminas.
AU549204B2 (en) Intravenously injectable immune serum globulin
MX9203439A (es) Una citocina mamifera, il-11
EG18379A (en) Novel pharmacological compounds
MY110217A (en) Use of l-deprenyl for retarding deterioration due to aging in dogs
ES8306714A1 (es) "procedimiento para la obtencion de un compuesto polipeptidico tiolado".
EP0230574A3 (en) Pharmaceutical compositions against infections caused by lav/htlv iii virus and the use thereof
OA06920A (fr) Halogénures d'ammonium spiro-quartenaire, leur procédé de préparation et leur utilisation dans un procédé de production de N-(2-pyrimidinyl) pipérazinyl-alkylazospiro-alcanédiones.
NO941327D0 (no) TCMTB på en bærer i pulverform, fremgangsmåte for fremstilling og fremgangsmåte for anvendelse
EP0339163A3 (en) Monoclonal antibodies specific for hiv and hybridomas for their production
GB1341794A (en) Medicament for the treatment of hepatic disorders
EP0160486A3 (en) Monoclonal antibodies
ATE15762T1 (de) Pharmazeutische zusammensetzungen mit gehalt an 7,8-dihydroxy-1-(hydroxy-phenyl)-2,3,4,5tetrahydro-1h-3-benzazepin-derivaten und an einem beta-adrenergischen blocker.
ES2027391T3 (es) Procedimiento de preparacion de ureas sustituidas.
GB1483650A (en) Pharmaceutical preparations based on mesterolone
GB1051686A (es)
GB1348449A (en) Benzodiazepine derivatives
DK499583D0 (da) Fremgangsmade til fremstilling af en isoquinolinforbindelse
ATE26214T1 (de) Pharmazeutische zusammensetzungen.
AU4070289A (en) Monoclonal antibody for inhibiting cell infection by hiv viruses
GB1164135A (en) Pharmaceutical Compositions Comprising Methdilazine Sulphoxide
SE7514774L (sv) Accelerator for fri-radikal katalyserad polymerisation.
DK222988D0 (da) Farmaceutiske praeparater indeholdende ornithin-decarboxylase-inhibitorer
IE36780L (en) Pharmaceutical preparations
GB1454390A (en) Nasal decongestants